Hot Investor Mandate: Venture Arm of a Global Innovation Group Invests in Early-Stage Biotech Companies Across All Indications

22 Oct

A firm founded in 2018 invests in early-stage biotech and pharma companies. The firm invests in seed to Series A investment while it can also provide later funding (follow-up investment). The firm also seeks to In-licensing and NewCo spinout for later-stage research projects. The firm also has 30,000+ square feet of chemistry/biology incubator space in the USA. The firm also shares the same investment philosophy with its parent company, a global innovation incubator and investment group supported by Chinese partners.

The firm mainly looks at the biopharmaceutical industry. The firm prefers to work closely with scientific innovators to advance discoveries rapidly through key value-inflection points.

The firm does not have specific company requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Firm Seeks Opportunities in Unmet Need Therapeutics, Diagnostics, Devices in Early Stages of Development

22 Oct

A newly established venture capital firm headquartered in Western Europe leverages the experienced resources from a dedicated life sciences consulting firm (a separate entity), and is able to invest in and support in early-stage technologies with a derisked strategy. The firm has a pan-European focus and is sourcing globally within industry, start-up communities, and business accelerators, for high potential opportunities.

The firm is interested in proprietary, differentiated therapeutic products addressing high-unmet medical need and platform technologies supporting next-generation patient diagnosis, treatment and disease prevention. The interest areas also include genomics, AI, diagnostics, medical devices, rare diseases, next generation personalized medicine, and more. The firm is interested in early-stage opportunities – pre-clinical assets with a valid proof of concept, devices with a working prototype are all good fits in terms of stage of development.

The firm will look at each opportunity carefully, and is most interested in those with business potential with a 3-5 year runway to strategic partnerships, acquisition by large life science companies or an IPO. The firm will prefer to lead investments and will take a very active role in their portfolio companies, often being involved in the operations of these companies to support their growth and enabling research that generates important, proof-of-concept data.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Venture Capital Firm Invests Up to $5M in Novel Digital Health Technologies in USA & Canada

22 Oct

A USA-based venture capital firm with a single LP looks to make growth-stage investments in the form of preferred equity, ranging from $1M-$5M initially, with additional capital reserved for follow-on financings, typically up to $10M over the life of the investment. The firm usually leads rounds, but is also open to syndicating with other investors. The firm looks to do 2-4 deals a year, and invests in U.S. and Canadian companies. Prospective companies may have some business overseas as long as they are headquartered in the U.S. or Canada.

The firm makes about one-half of its investments in healthcare, and is open to any healthcare companies that do not require FDA approval for their product/service. However, the firm focuses on B2B-oriented healthcare services and healthcare IT solutions. Some of the firm’s recent healthcare investments include a mobile telemedicine triage service company that provides mobile diabetic retinopathy eye exams as well as an EMR system to help orthopedic surgeons increase productivity.

The firm typically looks for growing companies with a run rate of at least $1M or a signed contract that would put them at a $1M run rate. The firm has no strict requirements in terms of management team, and will work with first-time entrepreneurs. The firm looks to take a board seat along with an investment.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Investment Firm Looks for Seed & Venture Stage Medical Device & Diagnostics Companies in North America, With West Coast USA Focus

22 Oct

A venture capital firm based in the USA has raised 3 funds to date and is currently investing out of its 3rd that closed at $20M. The firm makes primarily equity investments ranging from $250,000 to $5 million over the lifetime of the investment, with $100K-$500K as an initial investment. The firm has close relationships with several large Japanese medical technology corporations and also looks for ventures that they can introduce into the Japanese market. The firm prefers to invest in companies located in the West Coast if the US, although they are also open to review opportunities in North America.

The firm is looking for seed and venture-stage medical and diagnostic device companies. In these areas, the firm is most interested in single use therapeutic devices. The preferred regulatory pathway is a 510(k) submission, but PMA applications are also considered. Sectors with the most interest would be interventional  cardiovascular and neurovascular devices, less invasive surgical instrumentation, and point of care diagnostics. The firm remains open-minded to other types of devices and indications as well.

The firm looks for professionalism in a venture’s management team and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat in portfolio companies, however they look to add value by developing corporate partnerships in Japan at the appropriate time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Longevity, Health & Innovation – A Partnership Between LSN and MFA to Advance the Longevity Marketplace

15 Oct

Dr. Mary Furlong

An Interview with Dr. Mary Furlong, President and CEO, Mary Furlong and Associates

By Rory McCann, Marketing Manager & Conference Producer, LSN

With our inaugural Longevity, Health & Innovation conference fast approaching, I spoke to Dr. Mary Furlong, President and CEO of Mary Furlong and Associates, our partner for LHI. MFA is widely considered a leader in the longevity and aging marketplace, largely due to Mary’s experience in the space.

Listen below to find out more about how Mary got started, where she thinks the industry is going and the importance of events such as LHI in moving technologies and solutions forward.

Mary Furlong, Ed.D, MFA’s president and CEO, is a leading authority on the longevity marketplace. She has guided the business development and marketing strategies of leading corporations, emerging companies, and nonprofit organizations for more than 30 years.

Her list of clients/sponsors includes AARP, Caring.com, CareLinx, First Republic Bank, GreatCall Inc., Link•age, PetPlan, and UnitedHealthcare (UHC). Mary founded MFA in 2003 to help socially- and consumer-conscious companies understand the real needs of this growing market.

In addition, Mary is the Dean’s Executive Professor of Entrepreneurship at Santa Clara University’s Leavey School of Business.

Before launching MFA, Mary founded the nonprofit organization SeniorNet in 1986 and ThirdAge Media in 1996. Throughout the course of her work for both organizations, she raised $130 million in venture capital funds, corporate sponsorships, and foundation grants.

During Mary’s tenure, SeniorNet served more than 500,000 adults age 50 and older. Much of her time was spent in the field at the organization’s learning centers, observing the applications that worked and the issues related to the technology. ThirdAge Media reached more than 2 million members – most age 45 and older – when Mary served as its CEO and visionary leader of the editorial team.

Mary has appeared on CBS, PBS, NPR, and NBC’s Today show to discuss trends in aging and technology, and her expertise has been featured in The New York Times, USA Today, Business Week, Fortune, People, and Fast Company, among other publications.

In 2001, Fortune Small Business named Mary one of its “Top 25 Women Entrepreneurs,” and Time-honored her in 1999 as one of its “Digital 50.” She also served as a White House Commissioner on Libraries and Information Science during the Clinton administration, and she has conducted hearings on aging and technology for the U.S. Senate. She was named one of the 100 most influential women in Silicon Valley by the Silicon Valley Business Journal and has been a recipient of the ASA Leadership Award. Mary is an advisory member of the Ziegler Link•age Longevity Fund, L.P.

Mary is the author of Turning Silver into Gold: How to Profit in the New Boomer Marketplace, which was published in February 2007 by Financial Times Press. She also co-authored the book Grown-Up’s Guide to Computing, published by Microsoft Press in 1999.

Digital RESI November Innovator’s Pitch Challenge

15 Oct

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

Attending Digital RESI as a fundraising company is all about making connections with investors, strategic partners, service providers and other companies and entities that can help move your project to the next phase. One way for a company to maximize their visibility is the Innovator’s Pitch Challenge. Approved companies will upload a pre-recorded 4-minute pitch and take part in a livestreamed Q&A Session with a panel of expert investors. Furthermore, each participant will be featured on the Digital RESI Live Agenda with a dedicated landing page like this:

We caught up with Joe Camaratta (JC), President and CEO of Quantitative Radiology Solutions (QRS), to ask him about his own experience pitching at Digital RESI September.

How was your pitch session experience?

JC: The advice from the RESI team was invaluable in preparing our materials for our investor pitch.  In addition to advice on the pitch deck itself, the team provided examples of other collaterals useful in introducing our company to potential investors. The panel provided valuable advice on additional data to reinforce the importance of the problem that we are solving, and on our competitive differentiation.  I reached out to several members of the panel regarding further discussion of our technology. 

Did you have a productive RESI conference?

JC: QRS identified over 40 potential investors where our current raise would be a good fit for their investment philosophy. We were able to establish an introduction with many of them using the RESI partnering platform.  In addition, the panel sessions provided timely advice on how investors are adapting to the COVID-19 pandemic, and their expectations of entrepreneurs. 

Do you anticipate follow-up meetings with any investors from the session or from RESI?

JC: We have already followed-up with 10 investors to provide additional information around our opportunity. In addition, we continue to target those investors that we identified as potential fits but did not have time for a discussion at RESI. 

When asked about his participation as a panelist on live pitch Q&A sessions, Gary Gershony, a member of Life Science Angels said, “The pitch sessions at RESI were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.”

We are currently accepting applications for the Innovator’s Pitch Challenge at Digital RESI November on a first come, first serve basis. Don’t miss out on this valuable opportunity to pitch and connect with investors and strategic partners who are interested in learning more about your company!

Networking in a Virtual World: Optimizing Your Digital Conference Experience

15 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

In the world of digital events, virtual partnering, and Zoom fatigue, it’s more important than ever to stay connected, especially when fundraising, sourcing technology, or expanding a portfolio. Whether you’re thriving in slippers at your home office or itching to share cocktails and small plates (that you didn’t prepare) while networking, virtual partnering events can be a powerful asset to your fundraising and deal-flow.

The Life Science Nation (LSN) conference team has designed our digital events with the user in mind, for optimum convenience and connectivity. Take advantage of these elements and keep the conversations going!

Common Goal

When logging into a partnering platform, you know that every attendee you scroll through shares a common goal. The specifics of that goal may not line up with yours, but someone at a partnering event is there to make deals. With LSN’s partnering platform, we make it easy for participants to target and connect with those who are the right fit for technology, as well as stage of development. Whether you’re a seasoned partnering pro or new to the arena, a virtual format, as well as the LSN partnering platform, takes the guesswork out.

Equal Access

Have you ever attended a conference and witnessed an incredible presentation that spoke directly to you, only to find yourself 30-attendees-deep in a line to connect with the speaker? The virtual ecosystem provides equal access to speakers and industry leaders who may otherwise be tough to get facetime with. While there’s no guarantee the reception to a meeting request, your chances increase when you’re able to review a profile that communicates what the recipient is looking for… It might be you!

Interactive Features

Be sure to take advantage of live events and interactive features within the virtual event. One of the most popular aspects of the digital model is tailoring your experience, not only around your objectives and interest, but also around your schedule. Despite that convenience, many of the best conversations begin in live panels and interactive pitch sessions. If you’re able to join a panel or pitch to a live investor audience, even better! Virtual events like LSN’s make connection convenient, however, active participation in live features will give you a competitive edge.

If you’re dreaming of the days of in-person networking, we hope you’ll take advantage of the features available in the digital format. The game is afoot, and the best deals aren’t waiting. We hope to see you at Digital RESI November 17-19, and then again at the LSN Healthtech Partnering Week, January 14-15, 2021. Check out our newest events at 4D Meets AI and Longevity, Health & Innovation!

← Older Entries
Newer Entries →